Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis

Next Previous
Search
Trial Profile

A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ofatumumab (Primary) ; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ASCLEPIOS I
  • Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals

Most Recent Events

  • 18 Apr 2024 Results of Subgroup analysis from the Phase 3 ASCLEPIOS I/II Trials assessing prognostic value of Serum Neurofilament Light Chain for future disease activity according to BMI and age in Patients With Relapsing Multiple Sclerosis presented at the 76th Annual Meeting of the American Academy of Neurology 2024
  • 18 Apr 2024 Results from Phase 3 ASCLEPIOS I/II and ALITHIOS assessing longer-term (Up to 6 Years) Efficacy of Ofatumumab presented at the 76th Annual Meeting of the American Academy of Neurology 2024
  • 02 Mar 2024 Results of Subgroup analysis from the Phase 3 ASCLEPIOS I/II Trials assessing prognostic value of Serum Neurofilament Light Chain for future disease activity according to BMI and age in Patients With Relapsing Multiple Sclerosis presented at the Americas Committee for Treatment.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top